Ignite Creation Date:
2025-12-26 @ 11:12 PM
Ignite Modification Date:
2025-12-26 @ 11:12 PM
Study NCT ID:
NCT00547612
Status:
COMPLETED
Last Update Posted:
2012-03-16
First Post:
2007-10-19
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
Positron Emission Tomography Using [18F]-Labeled Substance P Antagonist Receptor Quantifier in Finding Disease in Patients With Pancreatic Cancer
Sponsor:
National Institutes of Health Clinical Center (CC)
Organization:
Study Overview
Official Title:
Pilot Trial of the NK1 Receptor Radio-Ligand [18F]SPA-RQ: Imaging Pancreatic Ductal Adenocarcinoma
Status:
COMPLETED
Status Verified Date:
2012-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
RATIONALE: Diagnostic procedures, such as positron emission tomography (PET) using \[18F\]-labeled substance P antagonist receptor quantifier, may be effective in finding disease in patients with pancreatic cancer.
PURPOSE: This phase I trial is studying how well a PET scan using \[18F\]-labeled substance P antagonist receptor quantifier works in finding disease in patients with pancreatic cancer.
PURPOSE: This phase I trial is studying how well a PET scan using \[18F\]-labeled substance P antagonist receptor quantifier works in finding disease in patients with pancreatic cancer.
Detailed Description:
OBJECTIVES:
* Determine whether \[18F\]-labeled substance P antagonist receptor quantifier positron emission tomography can identify pancreatic cancer evident on multiphase CT scan.
OUTLINE: Patients undergo multiphase CT scan of the chest, abdomen, and pelvis. No more than 15 days later, patients receive \[18F\]-labeled substance P antagonist receptor quantifier IV and undergo positron emission tomography over 6 hours.
Blood is collected periodically to measure the metabolism of the radiotracer by high performance liquid chromatography with radioactive detectors.
* Determine whether \[18F\]-labeled substance P antagonist receptor quantifier positron emission tomography can identify pancreatic cancer evident on multiphase CT scan.
OUTLINE: Patients undergo multiphase CT scan of the chest, abdomen, and pelvis. No more than 15 days later, patients receive \[18F\]-labeled substance P antagonist receptor quantifier IV and undergo positron emission tomography over 6 hours.
Blood is collected periodically to measure the metabolism of the radiotracer by high performance liquid chromatography with radioactive detectors.
Study Oversight
Has Oversight DMC:
Is a FDA Regulated Drug?:
Is a FDA Regulated Device?:
Is an Unapproved Device?:
Is a PPSD?:
Is a US Export?:
Is an FDA AA801 Violation?: